Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H19N5O2.ClH |
| Molecular Weight | 325.794 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C
InChI
InChIKey=GQJUGJHJUZSJLZ-UHFFFAOYSA-N
InChI=1S/C14H19N5O2.ClH/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2;/h7-8H,5-6H2,1-4H3,(H,15,18);1H
| Molecular Formula | C14H19N5O2 |
| Molecular Weight | 289.333 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Etazolate (EHT-0202) is a selective, positive GABAA receptor modulator has completed phase II clinical trials in patients with Alzheimer's disease. It is also a selective phosphodiesterase-4 inhibitor that is specific for cAMP. Etazolate showed anxiolytic and antidepressant activity and could be useful in managing post-traumatic stress disorder.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18397369 |
|||
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23384434 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. | 2011-03 |
|
| A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010-02-23 |
|
| Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. | 2008-07 |
|
| Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. | 2005-08-08 |
|
| Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits. | 1996-04-22 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00880412
2 capsules of study treatment (capsules of EHT0202 (ETAZOLATE) 40mg and or 80mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18397369
Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity. The neuroprotective effects of etazolate were fully blocked by GABA(A) receptor antagonists indicating that this neuroprotection was due to GABA(A) receptor signalling
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:52:31 GMT 2025
by
admin
on
Mon Mar 31 17:52:31 GMT 2025
|
| Record UNII |
7YO3254Y6B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000055478
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
7YO3254Y6B
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
35838-58-5
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
37274
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
C72768
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL356388
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
DTXSID4045767
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY | |||
|
163611
Created by
admin on Mon Mar 31 17:52:31 GMT 2025 , Edited by admin on Mon Mar 31 17:52:31 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |